Methyldopa

Hypertension, Hypertensive disease, Therapeutic procedure

Treatment

1 FDA approval

20 Active Studies for Methyldopa

What is Methyldopa

Methyldopa

The Generic name of this drug

Treatment Summary

Methyldopa is a drug used to lower blood pressure. It is an analog of DOPA and needs to be converted into an active form in order to have an effect on the body. It works by binding to alpha-2 adrenergic receptors, which helps lower the activity of the nerves that control blood vessel constriction. First approved in 1960, it is still used to treat hypertension, although newer drugs are available that are better tolerated. Methyldopa is sometimes given as an intravenous injection when oral therapy is not possible or to manage a hypertensive crisis.

Aldoril

is the brand name

image of different drug pills on a surface

Methyldopa Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Aldoril

Methyldopa

1962

32

Approved as Treatment by the FDA

Methyldopa, otherwise known as Aldoril, is approved by the FDA for 1 uses like Hypertensive disease .

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

Effectiveness

How Methyldopa Affects Patients

Methyldopa helps to lower blood pressure by targeting the body’s sympathetic nervous system and reducing the concentrations of certain hormones. It usually begins to work within 12 to 24 hours, and the maximum effect on blood pressure can be seen in 4 to 6 hours. The effects wear off after 24 to 48 hours when the drug is stopped. When taken intravenously, the effects can last for 10 to 16 hours.

How Methyldopa works in the body

Methyldopa works by blocking nerve signals that cause blood vessels to constrict. It is metabolized into two active compounds that bind to receptors in the brainstem, which in turn reduces the output of signals to the peripheral nervous system. This creates a calming, vasodilator effect, which lowers the blood pressure. Methyldopa also blocks an enzyme called DOPA decarboxylase, which helps make neurotransmitters like norepinephrine, but this plays only a small role in lowering blood pressure.

When to interrupt dosage

The recommended measure of Methyldopa is contingent upon the diagnosed condition, including Therapeutic procedure, Hypertensive crisis and Hypertensive disease. The amount of dosage also is dependent upon the mode of delivery (e.g. Intravenous or Tablet, film coated - Oral) identified in the table beneath.

Condition

Dosage

Administration

Hypertension

250.0 mg, , 500.0 mg, 50.0 mg/mL, 125.0 mg, 250.0 mg/mL

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet - Oral, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Liquid - Intravenous, Liquid

Hypertensive disease

250.0 mg, , 500.0 mg, 50.0 mg/mL, 125.0 mg, 250.0 mg/mL

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet - Oral, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Liquid - Intravenous, Liquid

Therapeutic procedure

250.0 mg, , 500.0 mg, 50.0 mg/mL, 125.0 mg, 250.0 mg/mL

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet - Oral, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Liquid - Intravenous, Liquid

Warnings

Methyldopa Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

history of liver disorders caused by methyldopa

Do Not Combine

Liver Diseases

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Methyldopa may interact with Pulse Frequency

There are 20 known major drug interactions with Methyldopa.

Common Methyldopa Drug Interactions

Drug Name

Risk Level

Description

Amifostine

Major

Methyldopa may increase the hypotensive activities of Amifostine.

Iobenguane

Major

The therapeutic efficacy of Iobenguane can be decreased when used in combination with Methyldopa.

Abacavir

Minor

Methyldopa may decrease the excretion rate of Abacavir which could result in a higher serum level.

Aclidinium

Minor

Methyldopa may decrease the excretion rate of Aclidinium which could result in a higher serum level.

Acrivastine

Minor

Methyldopa may decrease the excretion rate of Acrivastine which could result in a higher serum level.

Methyldopa Toxicity & Overdose Risk

The lowest amount of Methyldopa that has been found to be toxic in a female is 44 gm/kg taken intermittently. For rats, the toxic amount is 5000 mg/kg and for mice it's 5300 mg/kg. If someone overdoses on Methyldopa, they may experience low blood pressure, excessive drowsiness, slow heartbeat, dizziness, nausea and vomiting. Treatment for Methyldopa overdose includes gastric lavage or emesis, infusions, and monitoring of blood volume, electrolyte balance, and other body functions. Medications like levarterenol, epinephrine, and

image of a doctor in a lab doing drug, clinical research

Methyldopa Novel Uses: Which Conditions Have a Clinical Trial Featuring Methyldopa?

18 active clinical trials are currently evaluating the potential of Methyldopa to provide a therapeutic intervention, Hypertensive disease relief, and Hypertensive crisis management.

Condition

Clinical Trials

Trial Phases

Hypertension

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

Hypertensive disease

30 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Methyldopa Reviews: What are patients saying about Methyldopa?

5

Patient Review

10/12/2009

Methyldopa for High Blood Pressure

I was originally prescribed 250 mg twice daily, but my doctor increased the dosage to 500mg after three weeks in order to mitigate some of the more severe side effects (such as fainting). I have experienced dry mouth and dizziness at times, but those symptoms usually go away within a few days. I am also trying to conceive, so this medication was a better option for me than diovan. If you are thinking about starting this medication, I recommend talking to your doctor about slowly increasing the dose over time. This has worked well for me and has helped keep my blood pressure under control.

5

Patient Review

10/14/2009

Methyldopa for High Blood Pressure

Methyldopa has been a great switch for me. I was originally taking Micardis, but I didn't like it very much. Methyldopa has had no negative side effects that I've noticed and my blood pressure has been excellent since starting this medication.

4.7

Patient Review

6/4/2014

Methyldopa for High Blood Pressure

I was really lucky and didn't experience any negative side effects, except for my blood pressure going down. My nephrologist had me start taking it during my first pregnancy, and I took it for a few months after while trying to get pregnant again. So far so good!

3.7

Patient Review

10/12/2009

Methyldopa for High Blood Pressure

3.3

Patient Review

1/25/2016

Methyldopa for High Blood Pressure

I've been taking this medication for almost four years now, originally starting when I became pregnant. It's done a great job of managing my blood pressure, even during pregnancy. However, the only downside is that I feel constantly tired and fatigued.

3

Patient Review

7/25/2018

Methyldopa for High Blood Pressure

I sweat excessively and feel incredibly sluggish when I even try to walk a short distance.

2.7

Patient Review

2/5/2011

Methyldopa for High Blood Pressure

I began this medication when I became pregnant and was diagnosed with high blood pressure. The dosage was increased over time, but I still lost the baby. I'm wondering if there's a correlation here.

2

Patient Review

9/8/2011

Methyldopa for High Blood Pressure

I had a litany of terrible side effects while taking this medication, which did not effectively control my blood pressure. I spent more time in the hospital than at home while on this medicine, and would not recommend it to anyone.

2

Patient Review

5/7/2019

Methyldopa for High Blood Pressure

Unfortunately, this medication has caused more pain in my left side and chest tightness. I'm not sure what the next step should be.

2

Patient Review

4/20/2013

Methyldopa for High Blood Pressure

My feet, ankles, and legs were significantly swollen.

1.7

Patient Review

3/21/2013

Methyldopa for High Blood Pressure

I began this regimen yesterday, 250mg twice daily. I am feeling very ill and exhausted, to the point that I can't keep anything down. The pharmacy said to give it a couple days, but I'm not so sure. We are trying to conceive so they said this is my only route...

1.3

Patient Review

4/28/2010

Methyldopa for High Blood Pressure

I started taking this medication because we are trying to get pregnant and I was told that it would be safe for my baby. After one week of taking it twice a day, my blood pressure had lowered to 110/78 from 174/102. I did feel a little sleepy and dizzy after the first few doses, but those results were worth it to me.

1

Patient Review

11/14/2020

Methyldopa for High Blood Pressure

I've been on this medication for an extended period of time with no change in my condition. I've gradually increased the dosage as prescribed, and still see no difference. This is a total waste of time and money.

1

Patient Review

11/28/2010

Methyldopa for High Blood Pressure

I developed hypertension and was put on this medication. After eight months, the dosage was increased 500mg three times a day. This medicine worked for a while to lower my blood pressure; however, I stopped responding to the medication after a while. I also experienced fatigue, mood changes, and dizziness as side effects which led me to switch medications.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about methyldopa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the most common side effect of methyldopa?

"upset stomach

The more common side effects of methyldopa include: drowsiness, headaches, lack of energy, and upset stomachs."

Answered by AI

Is methyldopa an alpha blocker?

"Methyldopa works by binding to alpha(α)-2 adrenergic receptors, which leads to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals."

Answered by AI

Is methyldopa a beta blocker?

"2. Over time, alpha-methyldopa will often lower the total peripheral resistance, but the decrease in cardiac output is usually small, both when resting and during exercise. The beta-blockers lower blood pressure, but also lead to a significant decrease in cardiac output and heart rate."

Answered by AI

Why methyldopa is used in pregnancy?

"Methyldopa can help lower blood pressure and prevent pre-eclampsia, which can cause problems like preterm birth, low birth weight, and serious illness for both the mother and baby."

Answered by AI

Clinical Trials for Methyldopa

Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Have you considered Methyldopa clinical trials?

We made a collection of clinical trials featuring Methyldopa, we think they might fit your search criteria.
Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL

Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.

Waitlist Available
Has No Placebo

University of Alabama at Birmingham

Pankaj Arora, MD, FAHA

Have you considered Methyldopa clinical trials?

We made a collection of clinical trials featuring Methyldopa, we think they might fit your search criteria.
Go to Trials
Image of Wayne Health Mobile Units in Detroit, United States.

Text Message Reminders for High Blood Pressure

18+
All Sexes
Detroit, MI

This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB# 100221MP2A), the purpose of which is to improve cardiometabolic health in two uniquely comparable cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center involves separate but related projects that aim to improve cardiometabolic health outcomes through better risk factor control for three chronic conditions that are of tremendous public health importance, (hypertension (HTN), heart failure, and coronary heart disease), all of which contribute significantly to premature death in Detroit and Cleveland. The present study is the prospective observational cohort component of ACHIEVE P1- EPI (Project 1) of the ACHIEVE GREATER Center and serves to characterize the population of patients with blood pressure (BP) levels above normal attending The Wayne Health Mobile Health Unit (MHU) events to better understand key factors (e.g., social determinants of health) that convey information about baseline BP levels and related clinical outcomes (e.g., follow-up clinic visits, BP control, and cardiovascular events).

Recruiting
Has No Placebo

Wayne Health Mobile Units

Steven J Korzeniewski, PhD

Image of University of Alberta in Edmonton, Canada.

Egg White Powder for High Blood Sugar and High Blood Pressure

18 - 70
All Sexes
Edmonton, Canada

Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides. This is a feasibility study to assess the acute effect of IRW in egg white hydrolysate for the management of high sugar and blood pressure. Participants at high risk of type 2 diabetes (T2D) or having T2D will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing different protein powders. Each treatment will be separated by a minimum of 1-week. Participants in the healthy control group will undergo 1 treatment only (one day).

Phase 1
Recruiting

University of Alberta

Jianping Wu, PhD

Image of Northern Arizona University in Flagstaff, United States.

CardioCare Quest for High Blood Pressure

18+
All Sexes
Flagstaff, AZ

This project aims to address healthcare disparities among Navaho people diagnosed with hypertension or prehypertension through three main objectives. Firstly, it identifies and shares insights on healthcare access disparities affecting Navaho individuals experiencing nonadherence to hypertension treatment. Secondly, the proposal develops a telehealth solution based on factors identified as knowledge gaps caused by healthcare access disparities in hypertension management; we will use the factors to design a series of engaging minigames that can be incorporated into the larger CardioCare Quest. These minigames will be co-designed with end users and clinicians. Finally, the proposal conducts comprehensive qualitative and quantitative assessments of user experiences, perceptions, and challenges with CardioCare Quest.

Recruiting
Has No Placebo

Northern Arizona University (+1 Sites)

Tochukwu Ikwunne, PhD

Have you considered Methyldopa clinical trials?

We made a collection of clinical trials featuring Methyldopa, we think they might fit your search criteria.
Go to Trials